Curis (NASDAQ:CRIS) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a report issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their target price on shares of Curis from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, March 31st.

Curis Stock Performance

Shares of NASDAQ:CRIS opened at $1.17 on Monday. The firm has a market capitalization of $9.93 million, a PE ratio of -0.15 and a beta of 3.51. Curis has a 52-week low of $1.02 and a 52-week high of $16.99. The firm has a fifty day moving average of $2.55 and a 200 day moving average of $3.54.

Curis (NASDAQ:CRIS) last issued its earnings results on Monday, March 31st. The biotechnology company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.11. The company had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $2.04 million. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%. On average, sell-side analysts forecast that Curis will post -7.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC bought a new position in Curis in the fourth quarter worth $35,000. Millennium Management LLC grew its position in shares of Curis by 92.6% in the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after buying an additional 12,287 shares during the period. Focused Wealth Management Inc increased its stake in shares of Curis by 9.5% in the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 5,138 shares in the last quarter. Geode Capital Management LLC boosted its stake in Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 17,820 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in Curis in the fourth quarter worth about $607,000. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.